PDCD1 and head and neck squamous cell carcinoma: In the latter analysis by Hanna et al. the tumors of 126 HNSCC patients treated with anti-PD-1/anti-PD-L1 therapy at a single center were evaluated by massively parallel sequencing and immune profiling.